About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 7364 record(s)
Req # A-2024-000530
If the Nov 2023 Liraglutide Abbreviated New Drug Submission (ANDS) has received a Notice of Deficiency (NOD); a Notice of Non-Compliance (NON); a NOD-Withdrawal (NOD-W); or a NON-Withdrawal (NON-W), provide the month and year that the notice was…Organization: Health Canada
October 2024
Req # A-2024-000532
A screenshot of the status page for the April 2024 Liraglutide Abbreviated New Drug Submission (ANDS) on the Drug Submission Tracking System (DSTS) interface.Organization: Health Canada
October 2024
Req # A-2024-000569
The number of requests for exemption under subsection 56(1) of the Controlled Drugs and Substances Act (CDSA) to possess and use psilocybin by province and territory, that were received by the Minister of Health in 2019, 2020, 2021, 2022, 2023, and…Organization: Health Canada
October 2024
Req # A-2024-000623
For the time period — October 17, 2018, to December 31, 2023 — the general companion totals to the aggregate data requested under A-2024-000151. If possible, further disaggregate the data disclosed under A-2024-000151 relating to Part 11 according…Organization: Health Canada
October 2024
Req # A-2024-000634
Number of psilocybin access requests submitted and granted since January 2022 under the Special Access Program; Number of exemption requests submitted and granted under subsection 56(1) of the Controlled Drugs and Substances Act (between 2020-2022…Organization: Health Canada
October 2024
Req # A-2024-000645
With respect to generic drug in Health Canada's list of "Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredient mesalazine, the following documents that post-date August 2023: Notice of Deficiency (NOD),…Organization: Health Canada
October 2024
Req # A-2024-000649
All enquiries and responses produced by Health Canada under the general mailbox brdd.dgo.enquiries@hc-sc.gc.ca related to conditions approved for, dosage, use, conditions of use and restrictions and all other information transmitted for the drugs…Organization: Health Canada
October 2024
Req # A-2024-000715
The Companionship of the Sacred Vine (CSV) was granted a Section 56 Religious Exemption on July 4, 2023 from Health Canada (HC). From time to time the CSV will request amendments to this exemption. An amendment was requested on February 27/2024 to…Organization: Health Canada
October 2024
Req # A-2024-000720
Review reports, records of discussion of biowaiver requirements and bioequivalence for Teva Canada Limited’s ACT PROGESTERONE INJECTION (Drug Identification Number (DIN) 02446820).Organization: Health Canada
October 2024
Req # A-2024-000731
Records generated from January 1, 2024 and September 10, 2024, regarding the summary of British Columbia’s Most Recent Quarterly Report on the consumption of cannabis and other controlled substances.Organization: Health Canada
October 2024